Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione
IRST185.04
Phase 2 small_molecule active
Quick answer
Xofigo 1100 kBq/mL solution for injection, DELTACORTENE 5 mg compresse, Decadron “4 mg/1 ml Soluzione iniettabile”, Docetaxel Accord 20 mg/1 ml concentrate for solution for infusion, SOLDESAM 0,2% gocce orali, soluzione for metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC) is a Phase 2 program (small_molecule) at Istituto Gentili S.r.l. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Istituto Gentili S.r.l.
- Indication
- metastatic castration resistant prostate cancer (mCRPC), symptomatic bone-only metastatic castration resistant prostate cancer (mCRPC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active